Comparing the current results to its competitors, Pliant Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.31 %, recorded in the same quarter.
Pliant Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 97.18 %
Pliant Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and biopharmaceutical industries, which are characterized by rapidly advancing technologies and significant competition. It faces competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Competitors challenge the company based on the technologies used and the development of product candidates. Many small biotechnology companies collaborate with large, established firms to support research, development, commercialization, or to combine treatment approaches that may compete with the company's products. The company expects increasing competition as new therapies, technologies, and data emerge, particularly in oncology and the treatment of solid tumors progressing on checkpoint inhibitors. Additionally, competition exists in recruiting qualified personnel, establishing clinical trial sites, enrolling patients, and acquiring complementary technologies.
September 10, 2024
Pliant Therapeutics Showcases Promising Bexotegrast Data at ERS International Congress 2024 Amidst Financial Challenges By South San Francisco, Calif. September 10, 2024 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company specializing in novel therapeutics for fibrotic diseases, recently presented new data from its Bexotegrast program at the European Respiratory Society (ERS) International Congress 2024. The congress, held from September 7 to 11 in Vienna, Austria, provided a global platform for Pliant Therapeutics to share its latest research developments with the international medical and scientific community.The European Respiratory Society International Congress is a premier ...
May 6, 2024
CSIMarket.com is excited to provide an update on the recent advancements made by Pliant Therapeutics in the development of bexotegrast, a potential ground-breaking treatment for Idiopathic Pulmonary Fibrosis (IPF). Pliant Therapeutics, a pioneering biopharmaceutical company, has announced a promising corporate update and shared its first quarter 2024 financial results, which shed light on the accelerated development of bexotegrast in IPF.In a significant stride towards expediting bexotegrast development, Pliant Therapeutics successfully implemented the adaptive Phase 2b/3 trial design of their BEACON-IPF pivotal study. This innovative trial design, aimed at optimizing and enhancing the efficiency of clinica...
April 2, 2024
Pliant Therapeutics Faces Revenue Decrease in Q2 2023, but Remains Competitive in Fibrotic Disease MarketSOUTH SAN FRANCISCO, Calif., April 02, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a renowned clinical-stage biotechnology company specializing in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, recently participated in various investor events during the month of April. Despite reporting a significant decrease in revenue for the second quarter of 2023, Pliant Therapeutics continues to maintain a strong position in the market compared to its competitors.In the highly competitive landscape of biotechnology, companies are constantly striving to develop innovat...
Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.
Propanc Biopharma Inc's business model involves developing and commercializing novel therapeutics for the treatment of pancreatic and colorectal cancer.
Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Sources:
Pliant Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pliant Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
